← Latest papers
📄 cell biology

Pharmacologic IRE1 Activation Rewires Cholesterol Metabolism to Suppress TH17 Differentiation

Pharmacologic activation of the IRE1 signaling arm suppresses TH17 cell differentiation by accelerating the degradation of HMGCR to limit intracellular cholesterol biosynthesis, offering a potential therapeutic strategy for treating TH17-driven inflammatory diseases.

Original authors: Sanchez Ortiz, K., Chatterjee, P., Dion, W., Pannikkat, M., Kutseikin, S., Basso, T., Sun, J., Mathur, P., Dikiy, S., Thaxton, J. E., Wiseman, L., Mendoza, A.

Published 2026-11-16
📖 5 min read🧠 Deep dive

Original authors: Sanchez Ortiz, K., Chatterjee, P., Dion, W., Pannikkat, M., Kutseikin, S., Basso, T., Sun, J., Mathur, P., Dikiy, S., Thaxton, J. E., Wiseman, L., Mendoza, A.

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The immune system relies on a sophisticated team of soldiers to protect the body from invaders. Among these, a specific group of white blood cells known as T cells acts as the central command, directing the response to threats. When the body encounters bacteria or fungi, these T cells can transform into specialized units called Th17 cells. These cells are essential for fighting infections at the body's barriers, such as the skin and the gut. However, when this transformation goes into overdrive, Th17 cells can cause the immune system to attack the body's own tissues, leading to chronic inflammatory conditions like psoriasis, inflammatory bowel disease, and multiple sclerosis. For decades, scientists have sought ways to calm these overactive cells without shutting down the entire immune defense. The challenge lies in finding a way to stop the Th17 cells from forming in the first place, rather than just trying to silence them after they have already caused damage.

A new study from researchers at The Scripps Research Institute and the University of North Carolina offers a fresh perspective on this problem by looking at the internal machinery of the cell. The team focused on a stress-response system inside cells called the unfolded protein response, which acts like a quality control manager when the cell is overwhelmed by the task of making proteins. One part of this system, a sensor called IRE1, usually helps cells cope with stress. The researchers discovered that they could use a specific drug to turn up the activity of this sensor, and in doing so, they could selectively stop Th17 cells from forming. The drug does not harm the cells or stop other types of T cells from working; it simply prevents the Th17 cells from completing their transformation.

The key to this discovery lies in how the cell manages its fuel. To become a Th17 cell, a T cell must rapidly build new membranes and signaling structures, a process that requires a significant amount of cholesterol. The researchers found that when they activated the IRE1 sensor with a drug called IXA4, the cell responded by breaking down the very enzyme responsible for making cholesterol. This enzyme, known as HMGCR, is the rate-limiting step in the production of cholesterol, meaning it controls the speed of the entire process. By triggering the cell to destroy this enzyme, the drug effectively cut off the supply of cholesterol needed for the Th17 cell to develop. Without this essential building block, the cell cannot complete its transformation into the inflammatory Th17 form.

To prove that this lack of cholesterol was the actual cause of the effect, the researchers performed a crucial test. They added cholesterol precursors—chemical building blocks that appear later in the production line—directly to the cells treated with the drug. When these precursors were supplied, the cells were able to bypass the blockage, restore their cholesterol levels, and successfully become Th17 cells again. This confirmed that the drug was not harming the cells in a general way but was specifically targeting the metabolic pathway required for Th17 differentiation. The team also tested a second, chemically different drug that activates the same IRE1 sensor, and it produced the exact same result, reinforcing that the mechanism was real and consistent.

The study went beyond the laboratory dish to see if this effect held true in living animals. The researchers used a model where mice were exposed to a specific gut bacteria known to naturally trigger the growth of Th17 cells in the intestine. When these mice were given the drug orally, the expected surge in Th17 cells did not happen. The drug successfully prevented the bacteria from driving the formation of these inflammatory cells within the gut tissue. Importantly, the drug did not stop the mice from developing other types of T cells, such as those that fight viruses or those that regulate the immune system to prevent autoimmunity. This selectivity suggests that the Th17 cell is uniquely dependent on this specific metabolic pathway during its development, making it vulnerable to this intervention while leaving other immune functions intact.

The findings suggest that the IRE1 sensor acts as a metabolic checkpoint for Th17 cells. While the sensor is naturally active during normal cell development, the researchers showed that artificially boosting its activity creates a bottleneck in cholesterol production that the Th17 cell cannot overcome. This is distinct from previous ideas that suggested blocking the sensor would stop these cells; instead, the study shows that pushing the sensor to work harder is what creates the therapeutic effect. The researchers also noted that this approach avoids the side effects seen with current treatments that target the cytokines these cells produce, which can sometimes worsen certain conditions or leave patients vulnerable to infections. By targeting the cell's internal fuel supply rather than its output, this strategy offers a more precise way to limit the specific immune response that drives inflammation.

This work identifies a new way to think about treating inflammatory diseases. Instead of trying to block the signals that tell Th17 cells to attack, the researchers found a way to stop the cells from ever becoming the attackers in the first place. The ability to selectively suppress this one type of cell without disrupting the rest of the immune system is a significant step forward. The study provides a clear mechanism for how a drug can rewire cell metabolism to change cell fate, offering a potential path for developing new therapies that target the root causes of chronic inflammation rather than just managing the symptoms.

Drowning in papers in your field?

Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.

Try Digest →